181 related articles for article (PubMed ID: 38613829)
1. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.
Rees MJ; Kumar S
Am J Hematol; 2024 Aug; 99(8):1560-1575. PubMed ID: 38613829
[TBL] [Abstract][Full Text] [Related]
2. [Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)].
;
Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):430-435. PubMed ID: 38964916
[TBL] [Abstract][Full Text] [Related]
3. Variability of definition of high-risk multiple myeloma across phase III clinical trials.
Abu Za'nouneh FJ; Ababneh O; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
EJHaem; 2023 May; 4(2):454-458. PubMed ID: 37206288
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
Giri S; Grimshaw A; Bal S; Godby K; Kharel P; Djulbegovic B; Dimopoulos MA; Facon T; Usmani SZ; Mateos MV; Costa LJ
JAMA Oncol; 2020 Nov; 6(11):1759-1765. PubMed ID: 32970151
[TBL] [Abstract][Full Text] [Related]
5. Knowing the unknowns in high risk multiple myeloma.
Derman BA; Kosuri S; Jakubowiak A
Blood Rev; 2022 Jan; 51():100887. PubMed ID: 34479756
[TBL] [Abstract][Full Text] [Related]
6. Experts' consensus on the definition and management of high risk multiple myeloma.
Marcon C; Simeon V; Deias P; Facchin G; Corso A; Derudas D; Montefusco V; Offidani M; Petrucci MT; Zambello R; Stocchi R; Fanin R; Patriarca F
Front Oncol; 2022; 12():1096852. PubMed ID: 36755858
[TBL] [Abstract][Full Text] [Related]
7. Approach to High-Risk Multiple Myeloma.
Chen X; Varma G; Davies F; Morgan G
Hematol Oncol Clin North Am; 2024 Apr; 38(2):497-510. PubMed ID: 38195306
[TBL] [Abstract][Full Text] [Related]
8. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Wei M; Xie C; Huang J; Liu Q; Lai Y
Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
[TBL] [Abstract][Full Text] [Related]
9. How I treat high-risk multiple myeloma.
Zamagni E; Barbato S; Cavo M
Blood; 2022 May; 139(19):2889-2903. PubMed ID: 34727187
[TBL] [Abstract][Full Text] [Related]
10. Defining and Managing High-Risk Multiple Myeloma: Current Concepts.
Costa LJ; Usmani SZ
J Natl Compr Canc Netw; 2020 Dec; 18(12):1730-1737. PubMed ID: 33285523
[TBL] [Abstract][Full Text] [Related]
11. MUK
Brown S; Sherratt D; Hinsley S; Flanagan L; Roberts S; Walker K; Hall A; Pratt G; Messiou C; Jenner M; Kaiser M;
BMJ Open; 2021 Mar; 11(3):e046225. PubMed ID: 33762245
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Management of high-risk Myeloma: an evidence-based review of treatment strategies.
Lehners N; Hayden PJ; Goldschmidt H; Raab MS
Expert Rev Hematol; 2016 Aug; 9(8):753-65. PubMed ID: 27337562
[TBL] [Abstract][Full Text] [Related]
14. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.
Hagen P; Zhang J; Barton K
Blood Cancer J; 2022 May; 12(5):83. PubMed ID: 35637223
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
16. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
Green DJ; Bensinger WI
Curr Hematol Malig Rep; 2017 Feb; 12(1):61-67. PubMed ID: 28144893
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
Cerchione C; Usmani SZ; Stewart AK; Kaiser M; Rasche L; Kortüm M; Mateos MV; Spencer A; Sonneveld P; Anderson KC
Front Oncol; 2022; 12():820768. PubMed ID: 35211412
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myeloma.
Smith ML; Newland AC
QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
[TBL] [Abstract][Full Text] [Related]
19. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.
Zanwar S; Kumar S
Leuk Lymphoma; 2021 Dec; 62(13):3087-3097. PubMed ID: 34304677
[TBL] [Abstract][Full Text] [Related]
20. The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.
Prideaux SM; Conway O'Brien E; Chevassut TJ
Bone Marrow Res; 2014; 2014():526568. PubMed ID: 25295194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
